

effectively report its results to the President, to Congress, to the Department of Health and Human Services and to the public.

The information will also aid in program refinement and continuous improvement. The more productive ACL/AoA's programs, the greater the

number of older adults have access to a higher quality of life. Therefore, in addition to the legislative mandate under the OAA, it is important for program integrity and function to evaluate the LTCOP.

To comment and review the proposed data collection please visit the ACL

website at <https://www.acl.gov/about-acl/public-input>.

### Estimated Program Burden

ACL estimates the burden associated with this collection of information as follows:

| Respondent/data collection activity                                  | Number of respondents | Responses per respondent | Hours per response | Annual burden hours |
|----------------------------------------------------------------------|-----------------------|--------------------------|--------------------|---------------------|
| Focus Group—Facility staff including participant information .....   | 16                    | 1                        | 0.33               | 5.3                 |
| Focus Group—Residents/family including participant information ..... | 24                    | 1                        | 1                  | 24                  |
| Interview—Stakeholders .....                                         | 40                    | 1                        | 1                  | 40                  |
| Survey—Facility Administrator .....                                  | 1840                  | 1                        | 0.33               | 607.2               |
| Survey—Former Ombudsmen .....                                        | 12                    | 1                        | 1                  | 12                  |
| Survey—SUA director .....                                            | 53                    | 1                        | 0.5                | 26.5                |
| Total: .....                                                         | 1985                  | .....                    | 4.16               | 715                 |

Dated: April 6, 2020.

**Mary Lazare,**

*Principal Deputy Administrator.*

[FR Doc. 2020-07668 Filed 4-10-20; 8:45 am]

**BILLING CODE 4154-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases.

*Date:* May 11, 2020.

*Time:* 12:00 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3E71, Rockville, MD 20892 (Telephone Conference Call).

*Contact Person:* Lee G. Klinkenberg, Ph.D., Scientific Review Program, Division of

Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3E71 Bethesda, MD 20892-9834, 301-761-7749, [lee.klinkenberg@nih.gov](mailto:lee.klinkenberg@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: April 7, 2020.

**Tyeshia M. Roberson,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020-07709 Filed 4-10-20; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Interinstitutional Agreement—Institution Lead: Graphene Oxide-Polycarbonate Track-Etched Nanosieve Platform for Sensitive Detection of Human Immunodeficiency Virus Envelope Glycoprotein

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Indian Patent Applications listed in the Supplementary Information section of this notice to Chaudhary Charan Singh Haryana Agricultural University (CCSHAU) located in Hisar, India.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 28, 2020 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Jasmine J. Yang, Ph.D., (Senior) Licensing and Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville, MD 20850-9702 Telephone: (240)-276-5530; Facsimile: (240)-276-5504 Email: [jasmine.yang@nih.gov](mailto:jasmine.yang@nih.gov).

### SUPPLEMENTARY INFORMATION:

#### Intellectual Property

Indian Patent Application Serial No. 201711002764, filed February 24, 2017 entitled "Graphene oxide-polycarbonate track-etched nanosieve platform for sensitive detection of human immunodeficiency virus envelope glycoprotein."

The patent rights in these inventions have been assigned and/or exclusively licensed to the CCS Haryana Agricultural University and Government of the United States of America as represented by the Secretary, Department of Health & Human Services.

The prospective patent license will be for the purpose of consolidating the patent rights to CCSHAU, the co-owners of said rights, for commercial development and marketing. Consolidation of these co-owned rights is intended to expedite development of the invention, consistent with the goals

of the Bayh-Dole Act codified as 35 U.S.C. 200–212.

The prospective patent license will be an exclusive in India and may be limited to those fields of use commensurate in scope with the patent rights. It will be sublicensable, and any sublicenses granted by CCSHAU will be subject to the provisions of 37 CFR part 401 and 404.

This technology discloses a graphene oxide-polycarbonate nanosieve electrochemical biosensor for the detection of HIV envelope glycoprotein. The nanosieve is comprised of a polycarbonate membrane layered with graphene oxide laminate, which is conjugated to a bispecific tetravalent antibody, “2Dm2m”, comprised of CD4 fused to a human domain targeting HIV-1 coreceptor binding domain that has high affinity to the HIV envelope glycoprotein gp140. The nanosieve is fitted between two Ag/AgCl electrodes to form an electrochemical nanobiosensor capable of detecting HIV virus (see attached figures). Binding of the HIV gp140 to 2Dm2m reduces the ionic current through the nanosieve biosensors, which functions as the marker of HIV presence. The biosensor has the potential to be a low-cost, portable and quick method for HIV viral load detection.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 2, 2020.

**Richard U. Rodriguez,**  
Associate Director, Technology Transfer  
Center, National Cancer Institute.

[FR Doc. 2020–07707 Filed 4–10–20; 8:45 am]

BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: AAV Mediated Exendin-4 Gene Transfer to Salivary Glands To Protect Subjects From Diabetes or Obesity

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Institute of Diabetes and Digestive and Kidney Disease and National Institute of Dental and Craniofacial Research, institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the United States, European and Canadian Applications listed in the Supplementary Information section of this notice to Kriya Therapeutics, Inc., located in Palo Alto, California, USA.

**DATES:** Only written comments and/or applications for a license which are received by the National Institute of Diabetes and Digestive and Kidney Disease’s Technology Advancement Office on or before April 28, 2020 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Vladimir Knezevic, MD, (Senior) Advisor for Commercial Evaluation, Technology Advancement Office, Building 12A, Room 3011, Bethesda, MD 20817–5632 (for business mail), Telephone: (301)–435–5560; Email: [vlado.knezevic@nih.gov](mailto:vlado.knezevic@nih.gov).

#### SUPPLEMENTARY INFORMATION:

##### Intellectual Property

I. U.S. Pat: 9,511,103 issued 2016–12–06, entitled “AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity” (HHS Reference Number E–142–2011–0–US–05).

II. U.S. Divisional Pat: 10,300,095 issued 2019–05–28, entitled “AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity” (HHS Reference Number E–142–2011–0–US–6).

III. European Patent National Stage: EP2709653 granted 2017–11–22, entitled “AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity” (HHS Reference Number E–142–2011–0EP–

04), validated in Great Britain, France and Germany.

IV. U.S. Patent Application No. 16/396,262 filed 2019–04–26, entitled “AAV Mediated Exendin-4 Gene Transfer to Salivary Glands to Protect Subjects from Diabetes or Obesity” (HHS Reference Number E–142–2011–0–US–10).

V. Canadian Application No. 2,833,623 filed 2012–04–19, entitled “AAV Mediated Exendin-4 Gene Transfer to Salivary Glands to Protect Subjects from Diabetes or Obesity” (HHS Reference Number E–142–2011–0–CA–03).

The patent rights in these inventions have been assigned or exclusively licensed to the Government of the United States of America.

The prospective exclusive license territory may be worldwide and in fields of use that may be limited to prevention and treatment of type-2 diabetes and obesity.

The above-listed patent portfolio covers inventions directed to gene therapy and specifically, expression vectors and therapeutic methods of using such vectors in the treatment of type-2 diabetes and obesity.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing. The prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Institute of Diabetes and Digestive and Kidney Disease receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially and may be made publicly available.

License applications submitted in response to this notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 1, 2020.

**Vladimir Knezevic,**  
Senior Advisor for Commercial Evaluation,  
Technology Advancement Office, National  
Institute of Diabetes and Digestive and Kidney  
Disease.

[FR Doc. 2020–07706 Filed 4–10–20; 8:45 am]

BILLING CODE 4140–01–P